Baird said it believes the recent Phase 2 study failure for Jazz Pharmaceuticals’ (JAZZ) drug suvecaltamide has favorable readthrough to Praxis Precision Medicines’ (NASDAQ:PRAX) drug ulixacaltamide ...
Source LinkBaird said it believes the recent Phase 2 study failure for Jazz Pharmaceuticals’ (JAZZ) drug suvecaltamide has favorable readthrough to Praxis Precision Medicines’ (NASDAQ:PRAX) drug ulixacaltamide ...
Source Link
Comments